Wall Street brokerages predict that Haemonetics Co. (NYSE:HAE) will post $255.38 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Haemonetics’ earnings. The lowest sales estimate is $252.00 million and the highest is $258.00 million. Haemonetics posted sales of $247.36 million in the same quarter last year, which would indicate a positive year over year growth rate of 3.2%. The company is scheduled to issue its next quarterly earnings report on Tuesday, February 4th.
According to Zacks, analysts expect that Haemonetics will report full-year sales of $1.00 billion for the current financial year, with estimates ranging from $997.60 million to $1.01 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $1.08 billion, with estimates ranging from $1.05 billion to $1.12 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Haemonetics.
HAE has been the topic of several research reports. Raymond James upped their target price on Haemonetics from $110.00 to $150.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Jefferies Financial Group upped their target price on Haemonetics from $125.00 to $140.00 and gave the company a “buy” rating in a report on Friday, August 2nd. ValuEngine lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, November 11th. Barrington Research reissued a “buy” rating and issued a $141.00 target price on shares of Haemonetics in a report on Monday, November 4th. Finally, JMP Securities upped their target price on Haemonetics to $145.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $144.80.
In related news, CEO Christopher Simon sold 50,869 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $137.43, for a total transaction of $6,990,926.67. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronald G. Gelbman sold 16,926 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $118.26, for a total value of $2,001,668.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 121,000 shares of company stock worth $15,503,844. Corporate insiders own 1.32% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Alpha Windward LLC acquired a new stake in Haemonetics in the 2nd quarter worth about $29,000. Financial Gravity Wealth Inc. acquired a new stake in Haemonetics in the 2nd quarter worth about $40,000. Harvest Fund Management Co. Ltd acquired a new stake in Haemonetics in the 2nd quarter worth about $42,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Haemonetics in the 3rd quarter worth about $58,000. Finally, Smithfield Trust Co. boosted its stake in Haemonetics by 18.8% in the 3rd quarter. Smithfield Trust Co. now owns 570 shares of the medical instruments supplier’s stock worth $72,000 after buying an additional 90 shares during the last quarter. 99.96% of the stock is currently owned by institutional investors and hedge funds.
Haemonetics stock traded up $0.62 during trading hours on Wednesday, hitting $120.47. The stock had a trading volume of 246,809 shares, compared to its average volume of 326,910. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.37 and a quick ratio of 1.35. The stock has a market capitalization of $6.07 billion, a price-to-earnings ratio of 50.41, a PEG ratio of 2.79 and a beta of 0.77. Haemonetics has a 1-year low of $80.24 and a 1-year high of $140.36. The stock’s fifty day moving average is $124.06 and its two-hundred day moving average is $118.77.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.